A model mimicking catabolic inflammatory disease; a controlled randomized study in humans

PLoS One. 2020 Nov 5;15(11):e0241274. doi: 10.1371/journal.pone.0241274. eCollection 2020.

Abstract

Objective: Inflammatory disease is catabolic and associated with insulin resistance, increased energy expenditure, lipolysis and muscle protein loss. The main contributors to these metabolic adaptations are inflammation, malnutrition and immobilisation. Controlled experimental models incorporating these central elements of hospitalisation are lacking. The aim of this study was to validate such a human experimental model.

Methods: In a randomized crossover design, six healthy young men underwent; (i) overnight fast (CTR), or (ii) exposure to systemic lipopolysaccharide (1 ng/kg) combined with 36-hour fast and bed rest (CAT). The difference in insulin sensitivity between CAT and CTR was the main outcome, determined by a hyperinsulinemic euglycemic glucose clamp. Palmitate, glucose, urea, phenylalanine and tyrosine tracers were infused to estimate metabolic shifts during interventions. Indirect calorimetry was used to estimate energy expenditure and substrate oxidation.

Results: Insulin sensitivity was 41% lower in CAT than in CTR (M-value, mg/kg/min): 4.3 ± 0.2 vs 7.3 ± 1.3, p<0.05. The median (min max) palmitate flux (μmol/min) was higher during CAT than in CTR (257.0 (161.7 365.4) vs 131.6 (92.3 189.4), p = 0.004), and protein kinetics did not differ between interventions. C-reactive peptide (mg/L) was elevated in CAT compared with CTR (30.57 ± 4.08 vs 1.03 ± 0.19, p<0.001). Energy expenditure increased by 6% during CAT compared with CTR (1869 ± 94 vs 1756 ± 58, p = 0.04), CAT having higher lipid oxidation rates (p = 0.01) and lower glucose oxidation rates (p = 0.03). Lipopolysaccharide caused varying abdominal discomfort 2 hours post-injection, which had disappeared the following day.

Conclusion: We found that combined systemic inflammation, fasting and bed rest induced marked insulin resistance and increased energy expenditure and lipolysis, rendering this controlled experimental model suitable for anti-catabolic intervention studies, mimicking clinical conditions.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Biomarkers / metabolism
  • Glucose Clamp Technique
  • Humans
  • Inflammation / pathology*
  • Insulin Resistance
  • Kinetics
  • Lipids / analysis
  • Models, Biological*
  • Muscle, Skeletal / metabolism
  • Proteins / analysis
  • Signal Transduction
  • Young Adult

Substances

  • Biomarkers
  • Lipids
  • Proteins

Grants and funding

This work was financially supported by grants to NM from Aarhus University (Denmark), the Danish Council for Independent Research (grant no. 0603-00479B), the Lundbeck foundation (R83-A8172), and the Aase and Ejnar Danielsen Foundation (N/A). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. URM and BC are employed at Arla Foods Ingredients Group P/S and Arla Foods amba, scientific experts in clinical nutrition and contributed to the study design and final drafting of the manuscript, but had no influence on data collection and analysis or decision to publish, as stated in the ‘Author contributions’ section. Arla as a commercial dairy company had no influence on the conduction of the study.